RxDoctor Payments Data

Don Dumont, MD

Pulmonary Disease · Munster, INNPI 1417916073

Payments from drug & device makers

$4,280in general payments, 2019–2025

Across 104 payments — averaging $41.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$1K
  • Covidien LP$797
  • Johnson & Johnson$570
  • Medical Device Business Services, Inc.$390
  • GSK$254
  • Boehringer Ingelheim$159
  • plus $628 from 11 others

What the payments were for

  • Travel & lodging$2,20251%
  • Food & beverage$2,06748%
  • Education$120%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,280 in reported general payments places this provider in the 60th percentile of 258 pulmonary disease providers in Indiana.

See all pulmonary disease providers in Indiana

Medicare billing

Part B allowed, 2024
$121,900
Medicare patients
505
Services billed
1,267

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate36$393,215
Trelegy ElliptaFluticasone/Umeclidin/Vilanter368$309,249
Breo ElliptaFluticasone/Vilanterol366$190,125
Spiriva RespimatTiotropium Bromide80$70,109
Incruse ElliptaUmeclidinium Bromide107$47,972
Spiriva HandihalerTiotropium Bromide38$30,835
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr52$29,158
Combivent RespimatIpratropium/Albuterol Sulfate28$25,126
Arnuity ElliptaFluticasone Furoate70$24,192
SymbicortBudesonide/Formoterol Fumarate52$18,200
DuleraMometasone/Formoterol34$14,037
XareltoRivaroxaban16$13,217
Albuterol Sulfate HfaAlbuterol Sulfate513$12,561
Fluticasone-SalmeterolFluticasone Propion/Salmeterol83$10,781
Advair HfaFluticasone Propion/Salmeterol17$9,586

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta, Arnuity Ellipta$254$600,696963 claims
Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat$159$488,450144 claims
AstraZenecaSymbicort, Pulmicort Flexhaler$61$21,77466 claims
Johnson & JohnsonXarelto$570$13,21716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 258 pulmonary disease providers in Indiana.

Other pulmonary disease in Munster

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →